Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Survival of Hodgkin Lymphoma Patients Treated with Novel Immunotherapies after Autologous Stem Cell Transplantation Failure: A Retrospective Analysis of the Italian Lymphoma Foundation (FIL)

Maura Nicolosi, Valentina Bozzoli, Sabino Ciavarella, Cattina Federica, Gloria Margiotta Casaluci, Ombretta Annibali, Alessia Castellino, Francesco Rotondo, Luigi Petrucci, Federica Cocito, Sofya Kovalchuk, Erika Meli, Natalia Cenfra, Sara Bigliardi, Angelo Fama, Stefano Volpetti, Barbara Botto, Benedetto Bruno, Francesco Zaja

Blood (2023) 142 (Supplement 1): 6219.

https://doi.org/10.1182/blood-2023-187563

Published: 2023

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 384.

https://doi.org/10.1182/blood-2021-153364

Published: 2021

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136633

Published: 2020

Journal Articles

Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi

Vittorio Stefoni, MD PhD, Paolo Corradini, Lorella Orsucci, MD, Stefano Volpetti, Lisa Argnani, Anna Dodero, Cinzia Pellegrini, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136917

Published: 2020

Journal Articles

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Carlo Visco, Francesco Rodeghiero, Alessandra Romano, Federica Valeri, Michele Merli, Giulia Quaresimini, Stefano Volpetti, Roberto M. Santi, Giuseppe Carli, Elisa Lucchini, Francesco Passamonti, Alessandro Rambaldi, Giovanna Motta, Alessandra Borchiellini, Emanuele S. G. d’Amore, Marco Ruggeri

Blood (2019) 134 (20): 1708–1711.

https://doi.org/10.1182/blood.2019001617

Published: 2019

Includes: Supplemental data

Journal Articles

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 2025.

https://doi.org/10.1182/blood-2019-130786

Published: 2019

Journal Articles

Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years

Blood (2018) 132 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2018-99-116060

Published: 2018

Journal Articles

The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Blood (2018) 132 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2018-99-114168

Published: 2018

Journal Articles

Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)

Blood (2018) 132 (Supplement 1): 1135.

https://doi.org/10.1182/blood-2018-99-113314

Published: 2018

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Blood (2016) 128 (22): 4161.

https://doi.org/10.1182/blood.V128.22.4161.4161

Published: 2016

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Blood (2016) 128 (22): 3007.

https://doi.org/10.1182/blood.V128.22.3007.3007

Published: 2016

Journal Articles

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

Vittorio Stefoni, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, MD, Francesco Pisani, Michele Merli, Carlo Visco, MD, Rossella Paolini, Vittorio Ruggero Zilioli, Luca Baldini, MD Prof, Nicola Di Renzo, Patrizia Tosi, Nicola Cascavilla, MD, Stefano Molica, MD, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2016) 128 (22): 2985.

https://doi.org/10.1182/blood.V128.22.2985.2985

Published: 2016

Journal Articles

LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL)

Blood (2015) 126 (23): 3985.

https://doi.org/10.1182/blood.V126.23.3985.3985

Published: 2015

Journal Articles

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

Francesco Zaja, Stefano Volpetti, Annalisa Chiappella, MD, Flavia Salvi, MD, Angelo M. Carella, Adalberto Ibatici, Pier Paolo Piccaluga, Stefano A. Pileri, Davide Rossi, MD PhD, Pier Luigi Zinzani, Caterina Patti, Umberto Vitolo, Alfonso D'Arco, Alessandra Tucci, Silvia Franceschetti, Andrea Evangelista, Valentina Lenti, Renato Fanin, Alessandro Levis

Blood (2014) 124 (21): 1755.

https://doi.org/10.1182/blood.V124.21.1755.1755

Published: 2014

Journal Articles

Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi

Francesco Zaja, Flavia Salvi, MD, Silvia Franceschetti, Gianluca Gaidano, Marco Ladetto, Manuela Zanni, Gian Matteo Pica, Angelo Michele Carella, Annalisa Chiappella, Stefano Volpetti, Pier Luigi Zinzani, Alfonso Maria D'Arco, Andrea Evangelista, Alessandra Tucci, Pier Paolo Piccaluga, MD, PhD, Stefano A. Pileri, Renato Fanin, MD, Alessandro Levis

Blood (2013) 122 (21): 3047.

https://doi.org/10.1182/blood.V122.21.3047.3047

Published: 2013

Journal Articles

Bendamustine Salvage Therapy for T-Cell Non Hodgkin Lymphoma

Francesco Zaja, Luca Baldini, Stefano Luminari, Andrés J.M. Ferreri, MD, Alberto Grossi, Flavia Salvi, Renato Zambello, Stefano Volpetti, Maria Cecilia Goldaniga, Renato Fanin

Blood (2012) 120 (21): 4860.

https://doi.org/10.1182/blood.V120.21.4860.4860

Published: 2012

NARROW

Survival of Hodgkin Lymphoma Patients Treated with Novel Immunotherapies after Autologous Stem Cell Transplantation Failure: A Retrospective Analysis of the Italian Lymphoma Foundation (FIL)

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years

The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL)

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi

Bendamustine Salvage Therapy for T-Cell Non Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only